Eisai’s US chair, global Alzheimer’s leader to retire weeks after Leqembi approval

Kyle LaHucik

Senior Reporter

Ivan Cheung, the global leader of Eisai’s Alzheimer’s apparatus, will retire at the end of July, the Japanese drugmaker said Tuesday, just four days after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eisai’s US chair, global Alzheimer’s leader to retire weeks after Leqembi approval

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

Sofinnova outlines $550M fund after IPOs and M&A deals

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

WuXi AppTec will sell cell and gene therapy business to private equity firm

FDA approves subcutaneous version of Bristol Myers' Opdivo

Ei­sai’s US chair, glob­al Alzheimer’s leader to re­tire weeks af­ter Leqem­bi ap­proval

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Eisai’s US chair, global Alzheimer’s leader to retire weeks after Leqembi approval

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

Sofinnova outlines $550M fund after IPOs and M&A deals

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

WuXi AppTec will sell cell and gene therapy business to private equity firm

FDA approves subcutaneous version of Bristol Myers' Opdivo